600 Hits in 1.8 sec

Recent advances in treating Parkinson's disease

Wolfgang H. Oertel
2017 F1000Research  
Oertel W, Schulz JB: Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016; 139 Suppl 1: 325-37. PubMed Abstract | Publisher Full Text 18.  ...  Espay AJ, LeWitt PA, Kaufmann H: Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord. 2014; 29(14): 1710-9.  ...  Phase IIIb completed Oertel et al. 2016 100 Quik et al. 2008 101 Hong et al. 2009 102 Modified from Oertel and Schulz 17 (2016).  ... 
doi:10.12688/f1000research.10100.1 pmid:28357055 pmcid:PMC5357034 fatcat:c3y7jgv6dnhkdewqmpivgedase

Stammzellbasierte Therapieansätze bei der Parkinson Krankheit

Wolfgang H. Oertel
2005 e-Neuroforum  
Wolfgang H.  ...  Stammzellbasierte Therapieansätze bei der Parkinson Krankheit Wolfgang H. Oertel Zellbasierte Therapieansätze bei neurodegenerativen Erkrankungen sind Gegenstand intensiver Forschung.  ... 
doi:10.1515/nf-2005-0404 fatcat:5ucaalfyabcv5il6opeqv4w3wm

Cytokines and epilepsy

Gang Li, Sebastian Bauer, Mareike Nowak, Braxton Norwood, Björn Tackenberg, Felix Rosenow, Susanne Knake, Wolfgang H. Oertel, Hajo M. Hamer
2011 Seizure  
after SE. 5 In another study of a rat SE model induced by lithiumpilocarpine, the expression of IL-6 mRNA peaked between 10 h and 16 h and returned to control levels within 5 days. 66 Conversely, it  ...  and remained significantly elevated for up to 72 h. 113 However, the role of FGF-2 in epileptogenesis is contested with various studies suggesting conflicting roles.  ... 
doi:10.1016/j.seizure.2010.12.005 pmid:21216630 fatcat:aq5n3be5rzg5hcdzjuxubovne4

Transdermal rotigotine for the perioperative management of restless legs syndrome

Birgit Högl, Wolfgang H Oertel, Erwin Schollmayer, Lars Bauer
2012 BMC Neurology  
The mean rotigotine maintenance dose at time of surgery was 3.1 ± 1.1 mg/24 h. For most interventions (95%), rotigotine dosing regimens were maintained during the perioperative period.  ...  Continuous transdermal delivery of the dopamine agonist rotigotine provides stable plasma levels over 24 h and may provide RLS patients with a feasible treatment option for perioperative situations.  ...  Figure 1 1 Design of the5-year open-label extension study with rotigotine transdermal patch in restless legs syndrome (adapted from Oertel et al. [19, 21] ).  ... 
doi:10.1186/1471-2377-12-106 pmid:23009552 pmcid:PMC3577642 fatcat:3btff6knvfhwlk7bkhq3xkia74

Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease

Sanne K. Meles, Wolfgang H. Oertel, Klaus L. Leenders
2021 Molecular Medicine  
Oertel is a Hertie Senior Research Professor (Charitable Hertie Foundation, Frankfurt/Main, Germany). Availability of data and materials Not applicable.  ... 
doi:10.1186/s10020-021-00327-x pmid:34530732 pmcid:PMC8447708 fatcat:sbyot2lqbvgcxbimjab4krztke

Reduced central sympathetic activity in Parkinson's disease

Heidrun H. Krämer, Gothje Lautenschläger, Michael Azevedo, Kathrin Doppler, Anne Schänzer, Christoph Best, Wolfgang H. Oertel, Iris Reuter, Claudia Sommer, Frank Birklein
2019 Brain and Behavior  
O RCI D Heidrun H.  ...  Patient group 2:15 patients suffering from early-to-intermediate stage idiopathic PD (median age: 62 years (IQR: 57.0-65 years); 6 women; H&Y 1: n = 6; H&Y 2: n = 7 H&Y 3: n = 2; URPDS III: median: 7.0  ... 
doi:10.1002/brb3.1463 pmid:31691543 pmcid:PMC6908869 fatcat:lvhenetf5fewnor6zrshzabth4

Inpatient treatment costs of status epilepticus in adults in Germany

Adam Strzelczyk, Susanne Knake, Wolfgang H. Oertel, Felix Rosenow, Hajo M. Hamer
2013 Seizure  
Oertel has received honoraria and/or research grants from Boehringer Ingelheim, Desitin, GlaxoSmithKline, Merck, Mundipharma, Novartis, Orion, Sharp & Dohme, Schwarz Pharma Neuroscience/UCB Pharma, Synosia  ... 
doi:10.1016/j.seizure.2013.08.003 pmid:23992788 fatcat:gxtvdwqfgbajjcmgkgilz5oybq

Preprohypocretin Polymorphisms in Parkinson Disease Patients Reporting "Sleep Attacks"

Ida Rissling, Yvonne Körner, Frank Geller, Karin Stiasny-Kolster, Wolfgang H. Oertel, J. Carsten Möller
2005 Sleep  
Study Objectives: Previously, we found a significant association between the dopamine D2 receptor gene polymorphism Taq IA and sudden onset of sleep in patients with Parkinson disease. Here we evaluated the association between the preprohypocretin (-909T/C), (-22C/T), and (-20C/A) polymorphisms and sudden onset of sleep in the same population of patients with Parkinson disease. Design: We conducted an association study analyzing the distribution of preprohypocretin polymorphisms in Germanic,
more » ... casian Parkinson disease patients with and without sudden onset of sleep, matched according to drug therapy, disease duration, sex, and age. Setting: Movement disorders section at a university hospital. Participants: 132 Parkinson disease patients with sudden onset of sleep and 132 Parkinson disease patients without sudden onset of sleep. Interventions: Blood samples were taken from each participant and used for DNA extraction. Polymorphisms were analyzed by established polymerase chain reaction protocols or direct sequencing. Measurements and Results: The variant allele T of the (-909T/C) preprohypocretin polymorphism was more commonly found in Parkinson dis-ease patients with sudden onset of sleep. Statistical analysis showed that there were significant differences in the genotype (P = .024) and allele (P = .018) distribution between both groups. For heterozygous and homozygous carriers of allele T, the genotype relative-risk estimates for the presence of sudden onset of sleep were 2.01 (95% confidence interval: 0.76-5.34) and 2.81 (95% confidence interval: 1.09-7.25), respectively. Conclusions: Our results show a significant association between the (-909T/C) preprohypocretin polymorphism and sudden onset of sleep in Parkinson disease. However, we could not demonstrate any interaction between the Taq IA and (-909T/C) polymorphisms with respect to the occurrence of sudden onset of sleep, suggesting that multiple genetic factors may contribute to the pathogenesis of this phenomenon.
doi:10.1093/sleep/28.7.871 pmid:16124668 fatcat:ks2p7mwgkvc5hnjt674pvodukm

Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease

Andreas Wentrup, Wolfgang H Oertel, Richard Dodel
2009 Drug Design, Development and Therapy  
The 9.5 mg/24 h patch has equal efficacy to the capsules and reduces gastrointestinal adverse events, such as nausea and vomiting, by two-thirds.  ...  In the second layer, the drug is incorporated into an acrylic matrix, which ensures effective storage of rivastigmine (Oertel et al 2007) .  ...  Improved compliance of the patient, and thus intake of the agent, is a signifi cant benefi t in the treatment of AD (Small et al 2005; Oertel et al 2007) .  ... 
pmid:19920911 pmcid:PMC2761169 fatcat:vw7lalgwlve7zdz5f76a7gbacu

Widespread microglial activation in multiple system atrophy

Dorothee Kübler, Tobias Wächter, Nicole Cabanel, Zhangjie Su, Federico E. Turkheimer, Richard Dodel, David J. Brooks, Wolfgang H. Oertel, Alexander Gerhard
2019 Movement Disorders  
Overview of clinical patient data including age and disease duration at study participation in years, UPDRS III, Hoehn and Yahr stage (H + Y), and Schwab and England scale (S + E).  ...  Patient number Age Disease duration UPDRS III H + Y S + E Autonomic Cerebellar Pyramidal L-Dopa response MSA-P 1 45 2 28 2 100 OH None yes No Possible 2 54 5 52 4 40  ... 
doi:10.1002/mds.27620 pmid:30726574 pmcid:PMC6659386 fatcat:bze5avzxizhsrlrynz7xndbcaq

Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults

Daniel Alvarez-Fischer, Julia Fuchs, François Castagner, Olivier Stettler, Olivia Massiani-Beaudoin, Kenneth L Moya, Colette Bouillot, Wolfgang H Oertel, Anne Lombès, Wolfgang Faigle, Rajiv L Joshi, Andreas Hartmann (+1 others)
2011 Nature Neuroscience  
DAT activity was determined in cultured cells treated or not with Engrailed by measuring [ 3 H]-dopamine uptake as described 45 .  ...  Accordingly, Engrailed (3 nM for 4 h) increased the levels of Ndufs1 and Ndufs3 (169% ± 16% and 363% ± 25%, respectively; Fig. 3a,b) in midbrain cultures.  ... 
doi:10.1038/nn.2916 pmid:21892157 fatcat:2fmckfjpcvccddlhj5egvu4e5u

Modulation of Human Motor Cortex Excitability by Single Doses of Amantadine

Janine Reis, Daniel John, Antje Heimeroth, Hans-Helge Mueller, Wolfgang H Oertel, Torsten Arndt, Felix Rosenow
2006 Neuropsychopharmacology  
(a) Placebo (MED), (b) 50 mg amantadine (MED 50), (c) 100 mg amantadine (MED 100). ' ¼ baseline values (BSL), K ¼ values 2.5 h after drug intake.  ...  Amantadine Serum Concentration Blood serum was taken 2.5 h after drug intake. We found a dose-dependent, almost linear increase in AMA serum levels.  ... 
doi:10.1038/sj.npp.1301122 pmid:16794570 fatcat:yhlidehqlnfddbnbzvopmymnva

Dopamine depletion impairs precursor cell proliferation in Parkinson disease

Günter U Höglinger, Pamela Rizk, Marie P Muriel, Charles Duyckaerts, Wolfgang H Oertel, Isabelle Caille, Etienne C Hirsch
2004 Nature Neuroscience  
To identify infrequently dividing precursors, we also injected mice eight times with 50 mg per kg (body weight) of BrdU at 6-h intervals over a 2-d period. The mice were killed 3 weeks later.  ...  Scale bars, 2 µm (f); 500 nm (g); 200 nm (h); 40 nm (i).  ...  (g-i) Successive magnifications of the boxed areas in f-h, respectively.  ... 
doi:10.1038/nn1265 pmid:15195095 fatcat:f7nqmxnqvnekvaf5zrouot6szy

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

Paola Piccini, Nicola Pavese, Peter Hagell, Jan Reimer, Anders Björklund, Wolfgang H. Oertel, Niall P. Quinn, David J. Brooks, Olle Lindvall
2005 Brain  
12 h after the last dose of antiparkinsonian medication) and following the intake of an individually standardized single dose of L-dopa, which was the same at each assessment.  ... 
doi:10.1093/brain/awh649 pmid:16246865 fatcat:3zvtxkgbsbftdafzwk7mey72jq

Dyskinesias following neural transplantation in Parkinson's disease

Peter Hagell, Paola Piccini, Anders Björklund, Patrik Brundin, Stig Rehncrona, Håkan Widner, Lesley Crabb, Nicola Pavese, Wolfgang H. Oertel, Niall Quinn, David J. Brooks, Olle Lindvall
2002 Nature Neuroscience  
H.) who was blind to the recording dates. Intrarater reliability (intraclass correlation, hyperkinesias = 0.98, dystonia = 0.88) was established a priori with separate video sequences 2 .  ...  committees in Lund, London and Munich. a Recorded at the time of the highest postoperative off-phase dyskinesia scores for each patient. b As assessed in practically defined 'off' (in the morning ≥12 h  ... 
doi:10.1038/nn863 pmid:12042822 fatcat:rqsjuwjwmzc65gyww6mrfopusm
« Previous Showing results 1 — 15 out of 600 results